Streetbeat News

ACHL

Achilles Therapeutics plc

https://www.achillestx.com

Industry

Biotechnology

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Open

1.04

Mkt cap

44M

Volume

411K

High

1.08

P/E Ratio

-0.64

52-wk high

1.76

Low

1.01

Div yield

N/A

52-wk low

0.63

Health care stocks experienced significant movements in Thursday's intraday session. Candel Therapeutics, TC BioPharm, Eiger BioPharmaceuticals, Macrogenics, Barinthus Biotherapeutics, and Curis saw notable gains, with increases ranging from 24.62% to 64.3%. Conversely, eFFECTOR Therapeutics, Achilles Therapeutics, Inotiv, Universe Pharmaceuticals, Kintara Therapeutics, and Carmell faced declines, with decreases ranging from 12.85% to 80.2%. The movements were attributed to various factors, including earnings releases and market dynamics.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 4:31 pm

Nasdaq rose 1% with ConAgra Brands reporting better-than-expected Q3 earnings, leading to a positive market sentiment. Real estate and healthcare sectors saw gains, while TC Biopharm, Allurion Technologies, and Candel Therapeutics experienced significant stock increases. Conversely, eFFECTOR Therapeutics, Achilles Therapeutics, and KWESST Micro Systems saw notable declines. Oil prices slightly dropped, while gold and silver prices increased.

Portfolio Pulse from Avi Kapoor

April 04, 2024 | 3:58 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. Tevogen Bio Holdings led the gainers with an 85.5% increase, while Telesis Bio experienced the largest drop among the losers, falling 11.8%. Other notable movers include Candel Therapeutics and Achilles Therapeutics, with the former rising 27.97% and the latter declining by 10% following its Q4 earnings release.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 12:09 pm

Achilles Therapeutics' shares dropped following the announcement of Q4 financial results and interim Phase I/IIa data from the CHIRON and THETIS studies on advanced cancers.